Related Experiment Video
Updated: Jul 23, 2025

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms
Published on: May 31, 2024
A tale of two inhibitors: diarylquinolines and squaramides
James Chen1,2, Damian C Ekiert1,2
1Department of Cell Biology, NYU School of Medicine, New York, NY, USA.
Abstract:
The diarylquinoline bedaquiline (BDQ) is an FDA-approved drug for the treatment of multidrug-resistant tuberculosis that targets the mycobacterial adenosine triphosphate (ATP) synthase, a key enzyme in cellular respiration. In a recent study, Courbon et al (2023) examine the interaction between Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ-876 and the squaramide inhibitor SQ31f, showing that both drugs prevent the rotatory motions needed for enzymatic function.
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Antihypertensive Drugs: Thiazide-Class Diuretics
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...

